Stock comparison
Haemonetics
Harmony Biosciences Holdings
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
HRMY
Harmony Biosciences Holdings
Market cap
$1.75B
Sector
Healthcare
Overall winner
Harmony Biosciences Holdings HRMY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | HRMY | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 67B | HAE |
| Benjamin Graham | 85A | 60C | HAE |
| Philip Fisher | 60C | 75B | HRMY |
| Peter Lynch | 54C | 62C | HRMY |
| Joel Greenblatt | 31F | 28F | HAE |
| Charlie Munger | 54D | 62C | HRMY |
| Terry Smith | 55D | 67B | HRMY |
Side-by-side metrics
| Metric | HAE | HRMY |
|---|---|---|
| Market cap | $2.98B | $1.75B |
| P/E (TTM) | 24.8x | 11.8x |
| EV/EBIT | 14.1x | 6.4x |
| ROIC (TTM) | 8.37% | 12.5% |
| Gross margin | 55.74% | 76.55% |
| Net margin | 7.29% | 16.2% |
| Revenue CAGR 5y | 7.65% | 29.85% |
| EPS CAGR 5y | 24.62% | 46.45% |
| Debt / Equity | 1.5x | 0.2x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- Market cap$2.98Bvs $1.75B+41%
HRMY leads on
- Debt / Equity0.2xvs 1.5x+85%
- Revenue CAGR 5y29.85%vs 7.65%+74%
- Net margin16.2%vs 7.29%+55%
- EV/EBIT6.4xvs 14.1x+54%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.